

**Supplementary Table S3 - Overview of TEAEs - Safety population**

<i>n</i> (%)	<b>PTX (<i>n</i>=46)</b>	<b>PWI (<i>n</i>=46)</b>	<b>PTI (<i>n</i>=48)</b>
Patients with any TEAE	43 (94%)	45 (98%)	47 (98%)
Patients with any grade 3-4 TEAE	5 (11%)	5 (11%)	16 (33%)
Patients with any treatment emergent SAE	2 (4%)	2 (4%)	2 (4%)
Patients with any TEAE leading to death	0	0	0
Patients with any Pre-specified monitoring Event	0	0	0
Patients with any TEAE leading to permanent treatment discontinuation	1 (2%)	2 (4%)	1 (2%)